Hologic (NASDAQ:HOLX) Cut to Neutral at Mizuho

Mizuho lowered shares of Hologic (NASDAQ:HOLX) from an outperform rating to a neutral rating in a research note published on Thursday morning, MarketBeat.com reports. The firm currently has $78.00 price objective on the medical equipment provider’s stock, up from their prior price objective of $70.00.

Several other brokerages have also issued reports on HOLX. Wall Street Zen lowered shares of Hologic from a “buy” rating to a “hold” rating in a research note on Wednesday, October 1st. Morgan Stanley increased their price objective on shares of Hologic from $65.00 to $69.00 and gave the company an “equal weight” rating in a research report on Thursday, July 31st. Evercore ISI set a $78.00 price objective on shares of Hologic and gave the company an “outperform” rating in a research report on Tuesday, October 7th. UBS Group increased their price objective on shares of Hologic from $65.00 to $70.00 and gave the company a “neutral” rating in a research report on Thursday, July 31st. Finally, Stephens downgraded shares of Hologic from an “overweight” rating to an “equal weight” rating and dropped their price target for the company from $78.00 to $76.00 in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and thirteen have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $79.23.

Hologic Stock Up 0.1%

Shares of NASDAQ HOLX opened at $73.99 on Thursday. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. Hologic has a 12 month low of $51.90 and a 12 month high of $84.39. The firm has a market capitalization of $16.46 billion, a PE ratio of 30.70, a price-to-earnings-growth ratio of 2.54 and a beta of 0.63. The firm has a fifty day simple moving average of $67.65 and a two-hundred day simple moving average of $63.99.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, topping the consensus estimate of $1.05 by $0.03. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same period in the prior year, the business earned $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Equities analysts expect that Hologic will post 4.28 earnings per share for the current year.

Insider Buying and Selling

In other Hologic news, CEO Stephen P. Macmillan sold 138,358 shares of the firm’s stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the sale, the chief executive officer owned 1,234,624 shares in the company, valued at approximately $82,682,769.28. This trade represents a 10.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Christiana Stamoulis sold 7,402 shares of the firm’s stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $73.07, for a total transaction of $540,864.14. Following the sale, the director owned 47,336 shares in the company, valued at approximately $3,458,841.52. The trade was a 13.52% decrease in their position. The disclosure for this sale can be found here. 1.88% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Hologic

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HOLX. Chung Wu Investment Group LLC bought a new stake in shares of Hologic during the second quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd raised its position in shares of Hologic by 193.6% during the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 273 shares during the last quarter. SJS Investment Consulting Inc. raised its position in shares of Hologic by 341.5% during the third quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 362 shares during the last quarter. Loomis Sayles & Co. L P bought a new stake in shares of Hologic during the second quarter valued at approximately $33,000. Finally, Zions Bancorporation National Association UT bought a new stake in shares of Hologic during the first quarter valued at approximately $34,000. Institutional investors own 94.73% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.